Roche Holding AG (SWX:ROP)
Switzerland · Delayed Price · Currency is CHF 403.40
+1.70 (0.42%)
Oct 30, 2026, 5:30 PM CET
Roche Holding AG Revenue
Roche Holding AG had revenue of 31.45B CHF in the half year ending June 30, 2026, with 2.26% growth. This brings the company's total for the last twelve months to 62.96B, down -0.83% year-over-year. In the year 2025, Roche Holding AG had annual revenue of 63.36B with 1.54% growth. That makes Roche Holding AG the 150th largest company in the world by revenue and 2nd in Switzerland.
Revenue (ttm)
62.96B
Revenue Growth
-0.83%
P/S Ratio
5.12
Revenue / Employee
609.78K
Employees
103,249
Market Cap
322.25B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Roche Holding AG breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 63.36B | 961.00M | 1.54% |
| Dec 31, 2024 | 62.40B | 1.95B | 3.23% |
| Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
| Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
| Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
| Dec 31, 2020 | 60.34B | -3.41B | -5.35% |
| Dec 31, 2019 | 63.75B | 4.25B | 7.15% |
| Dec 31, 2018 | 59.50B | 3.75B | 6.73% |
| Dec 31, 2017 | 55.75B | 3.11B | 5.91% |
| Dec 31, 2016 | 52.64B | 2.23B | 4.43% |
| Dec 31, 2015 | 50.40B | 537.00M | 1.08% |
| Dec 31, 2014 | 49.87B | 1.25B | 2.58% |
| Dec 31, 2013 | 48.61B | 1.17B | 2.46% |
| Dec 31, 2012 | 47.44B | 3.33B | 7.55% |
| Dec 31, 2011 | 44.11B | -5.05B | -10.28% |
| Dec 31, 2010 | 49.17B | -1.98B | -3.88% |
| Dec 31, 2009 | 51.15B | 3.25B | 6.78% |
| Dec 31, 2008 | 47.90B | -472.00M | -0.98% |
| Dec 31, 2007 | 48.38B | 4.94B | 11.38% |
| Dec 31, 2006 | 43.43B | 6.47B | 17.52% |
| Dec 31, 2005 | 36.96B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Novartis AG | 47.86B |
| Sandoz Group AG | 9.43B |
| Alcon | 8.78B |
| Lonza Group AG | 6.87B |
| Galderma Group AG | 4.79B |
| Galenica AG | 4.29B |
| Sonova Holding AG | 3.61B |
| Straumann Holding AG | 2.64B |
Roche Holding AG News
- 3 days ago - Roche strengthens cancer diagnostic portfolio with launch of test for differential diagnosis of mesothelioma - GlobeNewsWire
- 4 days ago - Roche receives CE Mark for cobas smart e immunoanalyser - TheFly
- 4 days ago - Roche receives CE Mark for cobas® smart e immunoanalyser, completing a portfolio that brings central-lab precision to healthcare settings ranging from small clinics to large hospital laboratories - GlobeNewsWire
- 5 days ago - Roche Targets Emerging Oncology Market With New Lung-Cancer Drug - WSJ
- 5 days ago - Genentech says Phase III Krascendo 1 study met primary, secondary endpoints - TheFly
- 5 days ago - Roche says divarasib cut risk of death 44% in lung cancer trial - Reuters
- 5 days ago - Genentech's Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer - Business Wire
- 5 days ago - Roche's divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer - GlobeNewsWire